TY - JOUR
T1 - Slower clearance of intravenous metformin in rats with acute renal failure induced by uranyl nitrate
T2 - Contribution of slower renal and non-renal clearances
AU - Choi, Young H.
AU - Lee, Inchul
AU - Lee, Myung G.
PY - 2010/1/31
Y1 - 2010/1/31
N2 - It has been reported that metformin was primarily metabolized via hepatic CYP2C11, 2D1, and 3A1/2 in rats. It has also been reported that the protein expression and/or mRNA levels of hepatic CYP2C11, 2D subfamily, and 3A1 have decreased, decreased, and increased, respectively, in U-ARF rats. Thus, pharmacokinetic changes of intravenous metformin in U-ARF rats were evaluated. Metformin was administered intravenously at a dose of 50 mg/kg to control and U-ARF rats. After i.v. administration of metformin to U-ARF rats, its time-averaged total body clearance was significantly slower (95.2% decrease) than controls. This could have been due to both significantly slower time-averaged renal clearance (99.1% decrease; due to a urine flow rate-dependent timed-interval renal clearance of the drug, a decrease in renal OCT2, and/or an impaired kidney function in U-ARF rats) and time-averaged non-renal clearance (83.8% decrease; due to a decrease in hepatic CYP2C11 and 2D subfamily in U-ARF rats).
AB - It has been reported that metformin was primarily metabolized via hepatic CYP2C11, 2D1, and 3A1/2 in rats. It has also been reported that the protein expression and/or mRNA levels of hepatic CYP2C11, 2D subfamily, and 3A1 have decreased, decreased, and increased, respectively, in U-ARF rats. Thus, pharmacokinetic changes of intravenous metformin in U-ARF rats were evaluated. Metformin was administered intravenously at a dose of 50 mg/kg to control and U-ARF rats. After i.v. administration of metformin to U-ARF rats, its time-averaged total body clearance was significantly slower (95.2% decrease) than controls. This could have been due to both significantly slower time-averaged renal clearance (99.1% decrease; due to a urine flow rate-dependent timed-interval renal clearance of the drug, a decrease in renal OCT2, and/or an impaired kidney function in U-ARF rats) and time-averaged non-renal clearance (83.8% decrease; due to a decrease in hepatic CYP2C11 and 2D subfamily in U-ARF rats).
KW - Hepatic CYP2C11 and 2D subfamily
KW - Metformin
KW - Pharmacokinetics
KW - Rats
KW - U-ARF
UR - http://www.scopus.com/inward/record.url?scp=74149090100&partnerID=8YFLogxK
U2 - 10.1016/j.ejps.2009.05.006
DO - 10.1016/j.ejps.2009.05.006
M3 - Article
C2 - 19454315
AN - SCOPUS:74149090100
SN - 0928-0987
VL - 39
SP - 1
EP - 7
JO - European Journal of Pharmaceutical Sciences
JF - European Journal of Pharmaceutical Sciences
IS - 1-3
ER -